Regentis Biomaterials (NYSEAMERICAN:RGNT) Trading Down 0.6% – Here’s What Happened

Shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) were down 0.6% during trading on Wednesday . The stock traded as low as $1.7401 and last traded at $1.80. 27,423 shares changed hands during mid-day trading, a decline of 34% from the average daily volume of 41,591 shares. The stock had previously closed at $1.81.

Regentis Biomaterials Stock Performance

The stock’s 50 day moving average price is $2.07 and its two-hundred day moving average price is $2.69.

Get Regentis Biomaterials alerts:

Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) last posted its earnings results on Friday, September 11th. The company reported ($0.22) earnings per share (EPS) for the quarter.

Institutional Trading of Regentis Biomaterials

A hedge fund recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials at the end of the most recent quarter.

About Regentis Biomaterials

(Get Free Report)

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.

Featured Stories

• Five stocks we like better than Regentis Biomaterials
• J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
• 2 Stocks Breaking Out Post-FOMC With One Thing in Common
• Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
• These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons

Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.